The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
- Mechanism
- Curator reviewed
About V24343 Scientists have long known that cannabis, which stimulates a receptor in the brain called the CB1 receptor, also stimulates appetite as evidenced by the hunger pangs or "munchies" often experienced by cannabis smokers. Blockade of these CB1 receptors by products like V24343 has been shown to cause weight loss and may reduce risk factors for obesity related disorders such as cardiovascular disease and type II diabetes.
- Primary indication
- Obesity related disorders such as cardiovascular disease and type II diabetesCurator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with V24343, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account